Moderna (MRNA) closed at $241.46 on November 5, 2026, down 6.5% from the previous close, on volume of 11,024,351 shares (30-day average 16,696,125).
Data as of November 5, 2026.
5-Nov-2026
These Are the Stocks Reporting Earnings Today – November 6, 2026
TipRanks (Fri, 6-Nov 4:00 AM ET)
Here are the major earnings before the open Friday
Seeking Alpha News (Thu, 5-Nov 6:00 PM ET)
Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
ACCESS Newswire (Thu, 5-Nov 5:20 PM ET)
3 things to look out for on Friday
Seeking Alpha News (Thu, 5-Nov 4:13 PM ET)
Polymarket Odds: Will MRNA, HUM, UAA Beat Earnings Tomorrow?
TipRanks (Thu, 5-Nov 1:49 PM ET)
Moderna to report Q3 amid valuation debate, cancer vaccine results: What to expect
Seeking Alpha News (Thu, 5-Nov 1:27 PM ET)
Moderna’s mRNA-1469 earns WHO advisory recommendation for the DRC’s Tumaini Phase 2/3 Ebola study
Market Chameleon (Thu, 5-Nov 3:30 AM ET)
Moderna says Ebola vaccine picked for Phase 2/3 trial in Africa
Seeking Alpha News (Wed, 4-Nov 11:49 AM ET)
Moderna Advances Testing of Updated COVID-19 Vaccines as Investors Await Results
TipRanks (Wed, 4-Nov 11:32 AM ET)
Moderna Updates Early-Stage EBV Vaccine Study: What MRNA Investors Should Watch
TipRanks (Wed, 4-Nov 11:31 AM ET)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna trades on the NASDAQ stock market under the symbol MRNA.
As of November 5, 2026, MRNA stock price declined to $241.46 with 11,024,351 million shares trading.
MRNA has a beta of 0.78, meaning it tends to be less sensitive to market movements. MRNA has a correlation of 0.01 to the broad based SPY ETF.
MRNA has a market cap of $95.76 billion. This is considered a Large Cap stock.
Last quarter Moderna reported $145 million in Revenue and -$1.97 earnings per share. This beat revenue expectation by $41 million and exceeded earnings estimates by $.10.
In the last 3 years, MRNA traded as high as $261.00 and as low as $22.28.
The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, QQQ, VOO, IVV, SPY.
MRNA has outperformed the market in the last year with a price return of +916.7% while the SPY ETF gained +9.7%. MRNA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +323.7% and -1.8%, respectively, while the SPY returned -4.7% and -5.2%, respectively.
MRNA support price is $241.44 and resistance is $275.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA shares will trade within this expected range on the day.
